This study will be restricted to all original articles of healthy adults (people not suffering from any diseases). We will exclude minors, pregnant women, those planning a pregnancy, and lactating women.
Conditions
Interventions
None listed
Sponsors
Kagome Co., Ltd.
Review Team Professor Hiroharu Kamioka, Department of Ecological Symbiotic Science, Tokyo University of Agriculture Dr. Takahiro Yoshizaki, Department of Food and Nutritional Sciences, Toyo University Ms. Mari Makishi, NARASHINO Media Center for Research &
Education, Media Net Center, TOHO University. Mr. Takuro Inoue, Innovation Division, Kagome Co., Ltd. Ms. Tomoka Okame, Innovation Division, Kagome Co., Ltd. Ms. Ayaka Tsutsumi, Innovation Division, Kagome Co., Ltd.
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (Study design) We will include randomized controlled trials (RCT), quasi randomized controlled trials (qRCT), non-randomized controlled trials (nonRCT), crossover trials, cohort studies, and case-control studies. We will include scientific papers and reports which give us enough research details. (A) SR on single ingestion of GABA (PICO) Participant: We will include people not suffering from any diseases. We will exclude minors, pregnant women, those planning a pregnancy, and lactating women. Intervention: We define a single ingestion of test food containing GABA as an intervention. Comparison: We define ingestion of test food not containing GABA or maintaining daily life as controls. Outcome measurement: We will evaluate brain waves, HRV and salivary markers (cortisol, alpha-amylase, CgA) as assessment indices of psychological stress. The secondary outcomes are biochemical markers (body surface temperature and reaction of the eye pupil towards a flash of light, et al.), physiological markers (blood markers (cortisol and ACTH, et al.) and salivary markers, et al.) and subjective assessment (POMS and VAS, et al.). (B) SR on continual ingestion of GABA (PI(E)CO) Participant: Same as (A) Intervention: We define continual ingestion of test food containing GABA as an intervention. Comparison 1: Same as (A) Exposure: We define continual ingestion of food containing GABA as an exposure. Comparison 2: We define eating no food containing GABA as non-exposure. If subgroup analysis of GABA intake amount has been conducted in a study, we define the least intake group as a non-exposure group. Outcome measurement: Same as (A) (Language) Eligibility is not restricted by language.
Exclusion criteria
Exclusion criteria: We will exclude cross-sectional studies because it will be difficult to interpret causal relationships between exposure and outcome. We will also exclude proceedings and unpublished studies.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| We will evaluate the effect by single or continual ingestion of GABA on brain waves, heart rate variability (HRV) and salivary markers (cortisol, alpha-amylase, chromogranin A (CgA)) reported as assessment indices of psychological stress. | — |
Secondary
| Measure | Time frame |
|---|---|
| We will evaluate the effect by single or continual ingestion of GABA on biochemical markers (body surface temperature and reaction of the eye pupil towards a flash of light, et al.), physiological markers (blood markers (cortisol and adrenocorticotropic hormone (ACTH), et al.) and salivary markers, et al.) and subjective assessment (the Profile of Mood States (POMS) and visual analogue scale (VAS), et al.) reported as assessment indices of psychological stress. | — |
Countries
Japan
Contacts
Public ContactKoichi Aizawa
Kagome Co., Ltd. Innovation Division
Outcome results
None listed